Michael Elliott Bigby, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sentinel Lymph Node Biopsy | 8 | 2019 | 701 | 2.340 |
Why?
|
| Skin Neoplasms | 18 | 2018 | 5662 | 1.690 |
Why?
|
| Melanoma | 17 | 2018 | 5462 | 1.600 |
Why?
|
| Evidence-Based Medicine | 17 | 2020 | 3611 | 1.450 |
Why?
|
| Dermatology | 14 | 2012 | 870 | 1.360 |
Why?
|
| Clindamycin | 2 | 2019 | 139 | 1.320 |
Why?
|
| Rifampin | 3 | 2019 | 315 | 1.270 |
Why?
|
| Dermatologic Agents | 4 | 2019 | 274 | 1.250 |
Why?
|
| Hidradenitis Suppurativa | 3 | 2019 | 153 | 1.220 |
Why?
|
| Warts | 5 | 2005 | 68 | 1.160 |
Why?
|
| Sunscreening Agents | 5 | 2011 | 132 | 0.990 |
Why?
|
| Tinea Versicolor | 2 | 2015 | 8 | 0.920 |
Why?
|
| Skin Diseases | 10 | 2014 | 1065 | 0.800 |
Why?
|
| Medical Records | 5 | 2009 | 1413 | 0.790 |
Why?
|
| Lymph Node Excision | 3 | 2018 | 1248 | 0.780 |
Why?
|
| Lichen Planus | 4 | 2009 | 57 | 0.770 |
Why?
|
| Isotretinoin | 4 | 2019 | 109 | 0.740 |
Why?
|
| Alopecia | 2 | 2020 | 381 | 0.690 |
Why?
|
| Keratosis, Actinic | 1 | 2019 | 74 | 0.660 |
Why?
|
| Platelet-Rich Plasma | 1 | 2020 | 177 | 0.630 |
Why?
|
| Lichen Planus, Oral | 2 | 2012 | 53 | 0.610 |
Why?
|
| Scabies | 2 | 2011 | 14 | 0.580 |
Why?
|
| Drug Eruptions | 7 | 2001 | 295 | 0.570 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2018 | 264 | 0.550 |
Why?
|
| Periodicals as Topic | 5 | 2009 | 1431 | 0.510 |
Why?
|
| Acne Vulgaris | 1 | 2019 | 297 | 0.500 |
Why?
|
| Meta-Analysis as Topic | 5 | 2018 | 1342 | 0.480 |
Why?
|
| Bibliometrics | 2 | 2009 | 339 | 0.460 |
Why?
|
| Mycosis Fungoides | 1 | 2014 | 163 | 0.430 |
Why?
|
| Cryotherapy | 5 | 2005 | 154 | 0.420 |
Why?
|
| Dermatitis, Atopic | 2 | 2011 | 653 | 0.410 |
Why?
|
| Standard of Care | 1 | 2015 | 562 | 0.410 |
Why?
|
| Publication Bias | 2 | 2009 | 161 | 0.390 |
Why?
|
| Anti-Bacterial Agents | 5 | 2019 | 7153 | 0.380 |
Why?
|
| Practice Guidelines as Topic | 7 | 2015 | 7276 | 0.380 |
Why?
|
| Evaluation Studies as Topic | 2 | 2011 | 1676 | 0.370 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 2906 | 0.360 |
Why?
|
| Probiotics | 1 | 2013 | 351 | 0.360 |
Why?
|
| Dermatitis, Contact | 4 | 1994 | 129 | 0.350 |
Why?
|
| Patient Selection | 3 | 2018 | 4214 | 0.350 |
Why?
|
| Ultraviolet Rays | 2 | 2011 | 1059 | 0.340 |
Why?
|
| Skin Tests | 1 | 2011 | 612 | 0.330 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 814 | 0.300 |
Why?
|
| Review Literature as Topic | 3 | 2008 | 333 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2018 | 9941 | 0.290 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 1825 | 0.290 |
Why?
|
| Diarrhea | 1 | 2013 | 1343 | 0.280 |
Why?
|
| Humans | 88 | 2020 | 742088 | 0.280 |
Why?
|
| Peer Review, Research | 1 | 2009 | 329 | 0.270 |
Why?
|
| Clothing | 2 | 2011 | 92 | 0.270 |
Why?
|
| Antifungal Agents | 2 | 2015 | 729 | 0.250 |
Why?
|
| Langerhans Cells | 4 | 1994 | 173 | 0.240 |
Why?
|
| Immunologic Factors | 1 | 2013 | 1575 | 0.240 |
Why?
|
| Salicylic Acid | 4 | 2005 | 55 | 0.240 |
Why?
|
| Griseofulvin | 1 | 2003 | 7 | 0.240 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 2211 | 0.230 |
Why?
|
| Tinea Capitis | 1 | 2003 | 12 | 0.230 |
Why?
|
| Hybridomas | 4 | 1994 | 452 | 0.230 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 3 | 1996 | 341 | 0.220 |
Why?
|
| T-Lymphocytes | 9 | 2000 | 10163 | 0.210 |
Why?
|
| Keratinocytes | 3 | 2002 | 797 | 0.200 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 7901 | 0.200 |
Why?
|
| Publishing | 1 | 2009 | 833 | 0.200 |
Why?
|
| Editorial Policies | 1 | 2006 | 451 | 0.200 |
Why?
|
| Cyclosporine | 1 | 2004 | 784 | 0.190 |
Why?
|
| Monophenol Monooxygenase | 1 | 2001 | 69 | 0.190 |
Why?
|
| Risk Assessment | 4 | 2018 | 23320 | 0.190 |
Why?
|
| Cimetidine | 3 | 2005 | 78 | 0.190 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 1901 | 0.190 |
Why?
|
| Permethrin | 1 | 2000 | 16 | 0.190 |
Why?
|
| Safety | 2 | 2003 | 1185 | 0.180 |
Why?
|
| Crohn Disease | 1 | 2013 | 2301 | 0.180 |
Why?
|
| Health Behavior | 1 | 2011 | 2630 | 0.170 |
Why?
|
| Quackery | 1 | 1998 | 6 | 0.170 |
Why?
|
| Bleomycin | 3 | 2005 | 499 | 0.170 |
Why?
|
| Herpes Genitalis | 1 | 2000 | 141 | 0.170 |
Why?
|
| Eczema | 1 | 2001 | 229 | 0.170 |
Why?
|
| Hepatitis C | 1 | 2009 | 1582 | 0.170 |
Why?
|
| Herpesvirus 2, Human | 1 | 2000 | 185 | 0.170 |
Why?
|
| Off-Label Use | 1 | 2020 | 169 | 0.170 |
Why?
|
| Terminology as Topic | 1 | 2006 | 1548 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2001 | 1788 | 0.170 |
Why?
|
| Herpes Zoster | 1 | 2001 | 264 | 0.160 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 11001 | 0.160 |
Why?
|
| Virus Activation | 1 | 2000 | 319 | 0.160 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 115 | 0.160 |
Why?
|
| Insecticides | 1 | 2000 | 195 | 0.160 |
Why?
|
| Tacrolimus | 1 | 2001 | 741 | 0.160 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2013 | 3695 | 0.160 |
Why?
|
| Biochemical Phenomena | 1 | 2017 | 56 | 0.160 |
Why?
|
| Placebo Effect | 1 | 2001 | 502 | 0.150 |
Why?
|
| Nevus, Pigmented | 1 | 1999 | 219 | 0.150 |
Why?
|
| Nephritis, Interstitial | 1 | 2018 | 156 | 0.150 |
Why?
|
| Trinitrobenzenes | 2 | 1994 | 46 | 0.150 |
Why?
|
| Methotrexate | 1 | 2004 | 1720 | 0.150 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 3649 | 0.140 |
Why?
|
| Psoriasis | 1 | 2004 | 898 | 0.130 |
Why?
|
| Malassezia | 1 | 2015 | 8 | 0.130 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1999 | 546 | 0.130 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2010 | 187 | 0.130 |
Why?
|
| Laboratories | 1 | 2019 | 461 | 0.130 |
Why?
|
| Scalp | 1 | 1998 | 380 | 0.130 |
Why?
|
| Hypopigmentation | 1 | 2015 | 41 | 0.130 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2000 | 1155 | 0.130 |
Why?
|
| Survival Rate | 3 | 2018 | 12773 | 0.130 |
Why?
|
| Cryosurgery | 1 | 2019 | 453 | 0.120 |
Why?
|
| Neuralgia | 1 | 2001 | 568 | 0.120 |
Why?
|
| Australia | 1 | 2018 | 1167 | 0.120 |
Why?
|
| Aftercare | 1 | 2000 | 860 | 0.120 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1990 | 821 | 0.120 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 1994 | 1470 | 0.120 |
Why?
|
| Mass Screening | 1 | 2010 | 5238 | 0.120 |
Why?
|
| Canada | 1 | 2019 | 2061 | 0.120 |
Why?
|
| Confidence Intervals | 1 | 2000 | 2970 | 0.120 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2001 | 933 | 0.120 |
Why?
|
| Drug Interactions | 1 | 2018 | 1458 | 0.120 |
Why?
|
| Edema | 1 | 1998 | 790 | 0.120 |
Why?
|
| Hyperpigmentation | 1 | 2015 | 112 | 0.120 |
Why?
|
| Interferon-alpha | 1 | 2018 | 895 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 4751 | 0.110 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1994 | 378 | 0.110 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 6483 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2018 | 1905 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2000 | 1820 | 0.110 |
Why?
|
| Hand Dermatoses | 2 | 1991 | 61 | 0.100 |
Why?
|
| Administration, Topical | 2 | 2002 | 688 | 0.090 |
Why?
|
| Pancreatitis | 1 | 2017 | 1090 | 0.090 |
Why?
|
| Immunotherapy | 3 | 2002 | 4414 | 0.090 |
Why?
|
| Mohs Surgery | 1 | 2012 | 197 | 0.090 |
Why?
|
| Haptens | 1 | 1989 | 166 | 0.090 |
Why?
|
| Lymph Nodes | 5 | 2015 | 3465 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2005 | 3306 | 0.090 |
Why?
|
| Receptors, Lymphocyte Homing | 3 | 1994 | 143 | 0.090 |
Why?
|
| Triglycerides | 1 | 2017 | 2450 | 0.090 |
Why?
|
| Calmodulin | 1 | 1990 | 209 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3471 | 0.090 |
Why?
|
| General Surgery | 1 | 2000 | 1633 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2001 | 4147 | 0.080 |
Why?
|
| Antigen Presentation | 1 | 1994 | 1284 | 0.080 |
Why?
|
| Antigens | 1 | 1994 | 1462 | 0.080 |
Why?
|
| Cell Line, Transformed | 2 | 2000 | 898 | 0.080 |
Why?
|
| Epidermis | 2 | 1989 | 527 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 6608 | 0.080 |
Why?
|
| Foot Dermatoses | 1 | 1988 | 44 | 0.080 |
Why?
|
| Cyanosis | 1 | 1988 | 83 | 0.080 |
Why?
|
| Risk | 1 | 2000 | 9679 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2000 | 9846 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 11039 | 0.070 |
Why?
|
| Treatment Outcome | 6 | 2005 | 62966 | 0.070 |
Why?
|
| Skin | 4 | 1994 | 4353 | 0.070 |
Why?
|
| Cell Movement | 2 | 2000 | 5212 | 0.070 |
Why?
|
| False Positive Reactions | 1 | 2009 | 981 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 19862 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 8621 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2001 | 13029 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 15530 | 0.070 |
Why?
|
| Occlusive Dressings | 1 | 2005 | 50 | 0.070 |
Why?
|
| Pyrazolones | 1 | 1985 | 9 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 7 | 1994 | 6382 | 0.070 |
Why?
|
| United States | 6 | 2019 | 69693 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 14720 | 0.060 |
Why?
|
| Tretinoin | 1 | 1988 | 516 | 0.060 |
Why?
|
| Tuberculosis | 1 | 2017 | 1904 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2004 | 4929 | 0.060 |
Why?
|
| Neoplasms | 1 | 2013 | 21596 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 7 | 2000 | 9274 | 0.060 |
Why?
|
| Skin Pigmentation | 1 | 2006 | 281 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2012 | 1027 | 0.060 |
Why?
|
| Female | 19 | 2017 | 379592 | 0.060 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 3 | 1993 | 906 | 0.060 |
Why?
|
| Incidence | 4 | 2010 | 20928 | 0.060 |
Why?
|
| Counseling | 1 | 2011 | 1521 | 0.060 |
Why?
|
| Prevalence | 3 | 2009 | 15194 | 0.060 |
Why?
|
| Fluconazole | 1 | 2003 | 146 | 0.060 |
Why?
|
| Epitopes | 1 | 1989 | 2569 | 0.060 |
Why?
|
| Lymphocyte Activation | 5 | 2002 | 5519 | 0.050 |
Why?
|
| Naphthalenes | 1 | 2003 | 194 | 0.050 |
Why?
|
| Immunophenotyping | 2 | 2000 | 1866 | 0.050 |
Why?
|
| Dendritic Cells | 3 | 1996 | 2723 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2000 | 9185 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 692 | 0.050 |
Why?
|
| Iceland | 1 | 2001 | 183 | 0.050 |
Why?
|
| Cell Degranulation | 1 | 2002 | 287 | 0.050 |
Why?
|
| Virus Cultivation | 1 | 2000 | 92 | 0.050 |
Why?
|
| Male | 14 | 2017 | 349538 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 3 | 1994 | 969 | 0.050 |
Why?
|
| Toluidines | 1 | 2000 | 19 | 0.050 |
Why?
|
| Turkey | 1 | 2000 | 237 | 0.050 |
Why?
|
| Ivermectin | 1 | 2000 | 42 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2000 | 108 | 0.040 |
Why?
|
| Life Style | 1 | 2011 | 3824 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2009 | 21719 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2001 | 711 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1989 | 2276 | 0.040 |
Why?
|
| Netherlands | 1 | 2004 | 2170 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2002 | 4414 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 1661 | 0.040 |
Why?
|
| MEDLINE | 1 | 1998 | 125 | 0.040 |
Why?
|
| Sunlight | 1 | 2000 | 325 | 0.040 |
Why?
|
| Dermis | 1 | 2000 | 207 | 0.040 |
Why?
|
| Cloning, Molecular | 3 | 2000 | 4322 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2002 | 1368 | 0.040 |
Why?
|
| Sweden | 1 | 2000 | 1343 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 1 | 2000 | 935 | 0.040 |
Why?
|
| Time Factors | 1 | 2018 | 40054 | 0.040 |
Why?
|
| Calcium | 1 | 1990 | 5753 | 0.040 |
Why?
|
| Laser Therapy | 1 | 2003 | 1071 | 0.040 |
Why?
|
| Adult | 8 | 2017 | 213712 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 2000 | 12958 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2010 | 3070 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2000 | 1341 | 0.030 |
Why?
|
| Research Design | 2 | 2005 | 5979 | 0.030 |
Why?
|
| Piroxicam | 2 | 1985 | 19 | 0.030 |
Why?
|
| Lymphoid Tissue | 1 | 1996 | 455 | 0.030 |
Why?
|
| Thiazines | 2 | 1985 | 38 | 0.030 |
Why?
|
| Cytoplasm | 2 | 1990 | 1539 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13655 | 0.030 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 1994 | 225 | 0.030 |
Why?
|
| Propionates | 2 | 1985 | 168 | 0.030 |
Why?
|
| Palmitic Acids | 1 | 1994 | 54 | 0.030 |
Why?
|
| Receptors, Cell Surface | 2 | 1994 | 2867 | 0.030 |
Why?
|
| Mast Cells | 1 | 2002 | 1544 | 0.030 |
Why?
|
| Hypertriglyceridemia | 1 | 2017 | 293 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2019 | 77098 | 0.030 |
Why?
|
| Patient Care | 1 | 2000 | 639 | 0.030 |
Why?
|
| Mice | 12 | 1996 | 81045 | 0.030 |
Why?
|
| Cell Line | 3 | 2000 | 15994 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2000 | 1969 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 1996 | 421 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2000 | 3139 | 0.030 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2012 | 19 | 0.030 |
Why?
|
| Europe | 1 | 1999 | 3339 | 0.030 |
Why?
|
| Chloroquine | 1 | 1994 | 280 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2002 | 2257 | 0.030 |
Why?
|
| Formaldehyde | 1 | 1994 | 353 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2000 | 19223 | 0.030 |
Why?
|
| Animals | 13 | 2002 | 168561 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2008 | 4369 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2001 | 2107 | 0.030 |
Why?
|
| Risk Factors | 3 | 2011 | 72145 | 0.030 |
Why?
|
| Albumins | 1 | 1994 | 568 | 0.020 |
Why?
|
| Carrier Proteins | 3 | 1994 | 5019 | 0.020 |
Why?
|
| Stevens-Johnson Syndrome | 2 | 1985 | 277 | 0.020 |
Why?
|
| Random Allocation | 1 | 1996 | 2425 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2000 | 3199 | 0.020 |
Why?
|
| Leg Ulcer | 1 | 1991 | 69 | 0.020 |
Why?
|
| Research | 1 | 2000 | 1999 | 0.020 |
Why?
|
| Demecolcine | 1 | 1990 | 18 | 0.020 |
Why?
|
| Cytochalasin B | 1 | 1990 | 74 | 0.020 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1990 | 57 | 0.020 |
Why?
|
| Interleukin-2 | 2 | 1994 | 1887 | 0.020 |
Why?
|
| Egtazic Acid | 1 | 1990 | 173 | 0.020 |
Why?
|
| Lymphocytes | 2 | 1996 | 2614 | 0.020 |
Why?
|
| Reference Values | 2 | 1994 | 4982 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 2130 | 0.020 |
Why?
|
| Multigene Family | 1 | 1993 | 1102 | 0.020 |
Why?
|
| Forecasting | 1 | 1998 | 2948 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1993 | 804 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2000 | 4024 | 0.020 |
Why?
|
| Recurrence | 1 | 2000 | 8333 | 0.020 |
Why?
|
| Isoquinolines | 1 | 1990 | 368 | 0.020 |
Why?
|
| Acrodermatitis | 1 | 1988 | 18 | 0.020 |
Why?
|
| Vagina | 1 | 1993 | 825 | 0.020 |
Why?
|
| Mice, Inbred Strains | 2 | 1989 | 1827 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 1996 | 9639 | 0.020 |
Why?
|
| Protein Kinase C | 2 | 1990 | 1227 | 0.020 |
Why?
|
| Raynaud Disease | 1 | 1988 | 67 | 0.020 |
Why?
|
| Teratogens | 1 | 1988 | 112 | 0.020 |
Why?
|
| Receptors, Drug | 1 | 1987 | 161 | 0.020 |
Why?
|
| Herpes Simplex | 1 | 1991 | 466 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1993 | 1423 | 0.020 |
Why?
|
| Middle Aged | 4 | 2009 | 213127 | 0.020 |
Why?
|
| Polymers | 1 | 1994 | 1618 | 0.020 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2012 | 545 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2001 | 53187 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2012 | 802 | 0.020 |
Why?
|
| Tubulin | 1 | 1990 | 695 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2000 | 6191 | 0.020 |
Why?
|
| Transcription Factors | 2 | 1996 | 12164 | 0.020 |
Why?
|
| Skin Transplantation | 1 | 1991 | 1074 | 0.020 |
Why?
|
| Musculoskeletal System | 1 | 1988 | 175 | 0.020 |
Why?
|
| Adolescent | 3 | 2017 | 85649 | 0.020 |
Why?
|
| Apoptosis | 1 | 2002 | 9715 | 0.020 |
Why?
|
| Patient Compliance | 1 | 1996 | 2680 | 0.020 |
Why?
|
| Meclofenamic Acid | 1 | 1984 | 24 | 0.020 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 1988 | 316 | 0.020 |
Why?
|
| Tolmetin | 1 | 1984 | 23 | 0.020 |
Why?
|
| Sulindac | 1 | 1984 | 29 | 0.020 |
Why?
|
| Salicylates | 1 | 1985 | 126 | 0.020 |
Why?
|
| Child | 2 | 2005 | 77478 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1998 | 5978 | 0.020 |
Why?
|
| Indomethacin | 1 | 1985 | 331 | 0.020 |
Why?
|
| Photosensitivity Disorders | 1 | 1984 | 78 | 0.020 |
Why?
|
| Ikaros Transcription Factor | 2 | 1996 | 214 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1993 | 2524 | 0.020 |
Why?
|
| Thymus Gland | 3 | 1996 | 1264 | 0.020 |
Why?
|
| Intestines | 1 | 1993 | 1923 | 0.020 |
Why?
|
| Foot | 1 | 1988 | 528 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1994 | 5975 | 0.010 |
Why?
|
| Acetates | 1 | 1985 | 312 | 0.010 |
Why?
|
| Eye | 1 | 1988 | 728 | 0.010 |
Why?
|
| Ibuprofen | 1 | 1985 | 235 | 0.010 |
Why?
|
| Cell Count | 1 | 1987 | 1831 | 0.010 |
Why?
|
| Atrophy | 1 | 1988 | 1576 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1987 | 1663 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1994 | 3617 | 0.010 |
Why?
|
| Down-Regulation | 1 | 1990 | 3001 | 0.010 |
Why?
|
| Hand | 1 | 1988 | 882 | 0.010 |
Why?
|
| Actins | 1 | 1990 | 2120 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1994 | 3381 | 0.010 |
Why?
|
| Pruritus | 1 | 1985 | 359 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1991 | 2231 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1994 | 10943 | 0.010 |
Why?
|
| Phosphorylation | 2 | 1990 | 8436 | 0.010 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 1987 | 849 | 0.010 |
Why?
|
| Central Nervous System | 1 | 1988 | 1354 | 0.010 |
Why?
|
| Hyaluronic Acid | 2 | 1994 | 489 | 0.010 |
Why?
|
| Piperazines | 1 | 1990 | 2488 | 0.010 |
Why?
|
| Spleen | 2 | 1996 | 2359 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1985 | 2372 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2000 | 39004 | 0.010 |
Why?
|
| Bone Marrow Cells | 2 | 1996 | 2513 | 0.010 |
Why?
|
| Anaphylaxis | 1 | 1984 | 746 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 4029 | 0.010 |
Why?
|
| Drug Hypersensitivity | 1 | 1984 | 883 | 0.010 |
Why?
|
| Molecular Sequence Data | 3 | 1994 | 18112 | 0.010 |
Why?
|
| Pyrazoles | 1 | 1985 | 1970 | 0.010 |
Why?
|
| Signal Transduction | 2 | 1994 | 23387 | 0.010 |
Why?
|
| Mitogens | 1 | 1993 | 232 | 0.010 |
Why?
|
| Palmitic Acid | 1 | 1994 | 154 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 1996 | 1866 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1994 | 829 | 0.010 |
Why?
|
| Clone Cells | 1 | 1996 | 1692 | 0.010 |
Why?
|
| Aspirin | 1 | 1985 | 3278 | 0.010 |
Why?
|
| Hospitals | 1 | 1986 | 3937 | 0.010 |
Why?
|
| Erythropoiesis | 1 | 1996 | 705 | 0.010 |
Why?
|
| Base Sequence | 2 | 1994 | 12797 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1996 | 1526 | 0.010 |
Why?
|
| Mutation | 1 | 1996 | 29717 | 0.010 |
Why?
|
| Cell Differentiation | 3 | 1996 | 11470 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 708 | 0.010 |
Why?
|
| Aged | 3 | 2017 | 162944 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1994 | 880 | 0.010 |
Why?
|
| Exons | 1 | 1996 | 2431 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1991 | 554 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1994 | 2085 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1993 | 1791 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1996 | 2126 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1994 | 2715 | 0.010 |
Why?
|
| Cell Fusion | 1 | 1989 | 297 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1996 | 1837 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1994 | 3133 | 0.000 |
Why?
|
| Germ-Line Mutation | 1 | 1994 | 1786 | 0.000 |
Why?
|
| Necrosis | 1 | 1991 | 1643 | 0.000 |
Why?
|
| Cell Division | 1 | 1994 | 4564 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1996 | 2941 | 0.000 |
Why?
|
| Pregnancy | 1 | 1988 | 29087 | 0.000 |
Why?
|
| Fluorescent Dyes | 1 | 1994 | 1915 | 0.000 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 6313 | 0.000 |
Why?
|
| Killer Cells, Natural | 1 | 1994 | 2133 | 0.000 |
Why?
|
| Transfection | 1 | 1993 | 5892 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 6171 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1994 | 4839 | 0.000 |
Why?
|
| RNA | 1 | 1993 | 2747 | 0.000 |
Why?
|
| Protein Binding | 1 | 1994 | 9387 | 0.000 |
Why?
|
| Mice, Transgenic | 1 | 1994 | 9735 | 0.000 |
Why?
|
| Liver | 1 | 1996 | 7470 | 0.000 |
Why?
|
| DNA | 1 | 1994 | 7289 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1989 | 13814 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 1994 | 21821 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 1987 | 12071 | 0.000 |
Why?
|